X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with Biocon Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs BIOCON LTD - Comparison Results

BIOCON LTD 
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES BIOCON LTD VENUS REMEDIES/
BIOCON LTD
 
P/E (TTM) x -819.1 36.6 - View Chart
P/BV x 0.2 4.9 4.9% View Chart
Dividend Yield % 0.0 1.5 -  

Financials

 VENUS REMEDIES   BIOCON LTD
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-16
BIOCON LTD
Mar-16
VENUS REMEDIES/
BIOCON LTD
5-Yr Chart
Click to enlarge
High Rs218496 44.0%   
Low Rs82397 20.7%   
Sales per share (Unadj.) Rs365.6174.3 209.8%  
Earnings per share (Unadj.) Rs1.544.8 3.3%  
Cash flow per share (Unadj.) Rs37.956.9 66.6%  
Dividends per share (Unadj.) Rs05.00 0.0%  
Dividend yield (eoy) %01.1 0.0%  
Book value per share (Unadj.) Rs382.5202.8 188.6%  
Shares outstanding (eoy) m11.44200.00 5.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.42.6 16.0%   
Avg P/E ratio x101.010.0 1,014.2%  
P/CF ratio (eoy) x4.07.8 50.5%  
Price / Book Value ratio x0.42.2 17.8%  
Dividend payout %011.2 0.0%   
Avg Mkt Cap Rs m1,71789,220 1.9%   
No. of employees `0001.04.4 23.1%   
Total wages/salary Rs m3246,363 5.1%   
Avg. sales/employee Rs Th4,100.77,894.5 51.9%   
Avg. wages/employee Rs Th318.01,441.2 22.1%   
Avg. net profit/employee Rs Th16.72,029.7 0.8%   
INCOME DATA
Net Sales Rs m4,18334,854 12.0%  
Other income Rs m20845 2.4%   
Total revenues Rs m4,20335,699 11.8%   
Gross profit Rs m8128,200 9.9%  
Depreciation Rs m4172,423 17.2%   
Interest Rs m380102 372.4%   
Profit before tax Rs m356,520 0.5%   
Minority Interest Rs m0-744 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m05,754 0.0%   
Tax Rs m182,569 0.7%   
Profit after tax Rs m178,961 0.2%  
Gross profit margin %19.423.5 82.5%  
Effective tax rate %51.639.4 130.9%   
Net profit margin %0.425.7 1.6%  
BALANCE SHEET DATA
Current assets Rs m2,77139,932 6.9%   
Current liabilities Rs m1,93116,276 11.9%   
Net working cap to sales %20.167.9 29.6%  
Current ratio x1.42.5 58.5%  
Inventory Days Days12554 233.5%  
Debtors Days Days5486 62.4%  
Net fixed assets Rs m5,32839,101 13.6%   
Share capital Rs m1141,000 11.4%   
"Free" reserves Rs m4,17738,591 10.8%   
Net worth Rs m4,37640,556 10.8%   
Long term debt Rs m1,91120,724 9.2%   
Total assets Rs m8,42884,816 9.9%  
Interest coverage x1.164.9 1.7%   
Debt to equity ratio x0.40.5 85.4%  
Sales to assets ratio x0.50.4 120.8%   
Return on assets %4.710.7 44.1%  
Return on equity %0.422.1 1.8%  
Return on capital %6.619.0 34.8%  
Exports to sales %030.7 0.0%   
Imports to sales %20.520.4 100.7%   
Exports (fob) Rs mNA10,717 0.0%   
Imports (cif) Rs m8587,105 12.1%   
Fx inflow Rs m011,789 0.0%   
Fx outflow Rs m8588,393 10.2%   
Net fx Rs m-8583,396 -25.3%   
CASH FLOW
From Operations Rs m4695,264 8.9%  
From Investments Rs m29-9,540 -0.3%  
From Financial Activity Rs m-46410,867 -4.3%  
Net Cashflow Rs m356,591 0.5%  

Share Holding

Indian Promoters % 32.9 40.4 81.3%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 0.2 8.4 2.1%  
FIIs % 0.6 10.7 5.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 19.9 333.7%  
Shareholders   20,121 109,995 18.3%  
Pledged promoter(s) holding % 36.4 0.0 90,900.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   GSK PHARMA  ASTRAZENECA PHARMA  DISHMAN PHARMA  PIRAMAL ENTERPRISES  NATCO PHARMA  

Compare VENUS REMEDIES With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Weak Finish to the Week Post Vishal Sikka's Exit as CEO of Infosys(Closing)

Share markets in India witnessed selling pressure, led by slump in shares of Infosys Ltd. after Vishal Sikka resigned as chief executive officer of the country's second-largest software services exporter.

Related Views on News

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Biocon: High Other Income And Licensing Income Drive Growth (Quarterly Results Update - Detailed)

Nov 7, 2016

Biocon has announced its 2QFY17. The company has reported 19.8% YoY growth in net sales and profits of Rs 1.5 bn for the quarter. Here is our analysis of the results.

Biocon: Lower R&D Expenses Help Margin Expansion (Quarterly Results Update - Detailed)

Sep 19, 2016

Biocon has announced its 1QFY17. The company has reported 21.1% YoY growth in total income and 34.6% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Aug 18, 2017 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 5-YR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS